The Oracle Speaks

Oraculum Loquitur

https://theoptionsoracle.com/

21 September 2014

Introducing The Rowboat

An advanced Covered Call system that is quite possibly The Holy Grail of Investing.

Step 1: Sell the Put

( This is a Cash Covered Put, I have to have enough Cash to buy 100 shares per contract if the option is exercised, this is also my maximum risk. )

SNSS @ $7.34

Sunesis Pharmaceuticals, Inc.

Sell To Open SNSS Oct14 $2.50 Put @ Market

Bid .40c / Time .43c

16% return in 25 days

$10,000 should generate $1600.00

 

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company’s lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML. It has completed a Phase III, randomized, double-blind, placebo-controlled, and pivotal clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AMl. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of PDK1. The company was founded in 1998 and is headquartered in South San Francisco, California.

Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
Phone: 650-266-3500
Fax: 650-266-3501
Website: http://www.sunesis.com

Sign up with a auto-trading company and let your broker do the trades for you.

News:

http://www.thestreet.com/story/12862083/1/sunesis-takes-a-run-through-the-feuerstein-ratain-rule.html?puc=yahoo&cm_ven=YAHOO

I expect the drug to fail and this gets cut in half.

Remember, no more than 5 or 10% of your portfolio should ever be exposed in any one trade or position.

Do not use Margin!

Example: if you have $30k total, each position can only be $3k exposure

 

Step 2:IF it got Put to us,Now we “Lock-in” a profit and complete the rowboat

Sell the Covered Call

(Do not buy the stock just to sell the covered Call)

We entered into 2 new long positions. (they got “Put” to us)

Normally we would Immediately sell the covered call, but not this time.

We are going to “Hold on both of them since the fundamentals have not changed. They are seriously Under Valued right now.

AMPE @ $3.48

Ampio Pharmaceuticals, Inc.

1y Target Est: $11.67

History:

Cost basis $5.00 per share.

Premiums collected: .55c per share

11% Return in 1 months

$10,000 would have generated $2100.00

actual trades:

09/20/2014 Buy AMPE @ $5.00

08/18/2014 Sell To Open AMPE Sep14 $5 Put $0.55

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee and Optina that is in Phase IIb clinical trial for diabetic macular edema. The company, through its subsidiaries, is also involved in the development and commercialization of RedoxSYS, an in-vitro diagnostic platform that measures human oxidation-reduction potential; and Zertane, an oral drug in late stage development as treatment for PE in men. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.

Ampio Pharmaceuticals, Inc.
5445 DTC Parkway
Suite 925
Greenwood Village, CO 80111
Phone: 720-437-6500
Fax: 720-437-6501
Website: http://www.ampiopharma.com

News: http://finance.yahoo.com/news/ampio-shares-fall-step-study-202503201.html

VHC @ $5.35

VirnetX Holding Corporation

1y Target Est: $42.33

History:

Cost basis $12.00 per share.

Premiums collected: $1.05 per share

8.5% Return in 1 months

$10,000 would have generated $850.00

actual trades:

08/18/2014 Sell To Open VHC Sep14 $12 Put $0.05

(Very bad fill)

Addendum: Silly me. I was looking at the wrong stock.

Corrected number are:

08/18/2014 Sell To Open VHC Sep14 $12 Put $1.05

VirnetX Holding Corporation develops software and technology solutions for securing real-time communications over the Internet. The company’s software and technology solutions include secure domain name registry and GABRIEL Connection Technology that are designed to secure various real-time communications over the Internet, as well as enable organizations and individuals to establish communities of secure, registered users, and transmit information between various devices, networks, and operating systems. These secure network communities are designed to support content applications, such as Instant messaging, voice over Internet protocol, mobile services, streaming video, file transfer, remote desktop, and Mobile-to-Mobile communications in a secure environment. It also intends to provide a portfolio of licenses and services comprising VirnetX technology; GABRIEL Connection Technology software development kit, including object libraries, sample code, testing and quality assurance tools, and supporting documentation required by customers to implement the company’s technology; domain name registrar service; registrar server software; connection server software; and relay server software, as well as technical support, and secure domain name master registry and connection services. The company serves developers and original equipment manufacturers of chips, servers, smart phones, tablets, e-Readers, laptops, net books, and other devices in the IP-telephony, mobility, fixed-mobile convergence, and unified communications markets. VirnetX Holding Corporation was incorporated in 2005 and is based in Zephyr Cove, Nevada.

VirnetX Holding Corp
308 Dorla Court
Suite 206
Zephyr Cove, NV 89448
Phone: 775-548-1785
Fax: 775-580-7527
Website: http://www.virnetx.com

News: http://finance.yahoo.com/news/uspto-terminates-patent-reexamination-proceedings-132600459.html

The patents Stand!

Remember, no more than 5 or 10% of your portfolio should ever go into any one trade or position.Example: if you have $30k total, each position can only be $3k exposure

 

How did we do last Month?

Expired Puts (Closed Positions)

Current/Older Positions/History

This includes a running total for each open position.

Do not enter these positions.

News:

CYTK @ $4.14

Cytokinetics, Incorporated

HOLD CYTK Nov14 $5 Call still cooking

History:

Cost basis $5.00 per share.

Premiums collected: .75c per share

15% Return in 4 months

actual trades:

08/18/2014 Sell To Open CYTK Nov14 $5 Call $0.10

05/19/2014 Sell To Open CYTK Aug14 $5 Call $0.40

05/16/2014 Buy CYTK – Stock Assignment $5.00

04/21/2014 Sell To Open CYTK May14 $5 Put $0.25

$10,000 would have generated $1500.00

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the treatment of heart failure. The company holds a license to develop and commercialize omecamtiv mecarbil and related compounds worldwide. It develops tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the United States Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics, Incorporated has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to develop a skeletal muscle activator structurally distinct from tirasemtiv, for non-neuromuscular indications. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Incorporated
280 East Grand Avenue
South San Francisco, CA 94080
Phone: 650-624-3000
Fax: 650-624-3010
Website:
http://www.cytokinetics.com

ONTY @ $2.09

HOLD ONTY Dec 14 $5 Call still cooking

History:

Cost basis $5.00 per share.

Premiums collected: 2.45 per share

49% Return in 33 months

$10,000 would have generated $4900.00

actual trades:

08/18/2014 Sell To Open ONTY Dec14 $5 Call$0.10

03/24/2014 Sell To Open ONTY May14 4 Call $0.15

03/18/2013 Sell To Open ONTY Jun13 5 Call $0.05

11/19/2012 Sell To Open ONTY Jan13 6 Call $0.55

05/21/2012 Sell To Open ONTY Nov12 7 Call $0.05

03/20/2012 Sell To Open ONTY May12 6 Call $0.05

03/16/2012 Buy ONTY – Option Assignment $5.00

03/16/2012 Buy To Close ONTY Mar12 $5 Put

02/21/2012 Sell To Open ONTY Mar12 $5 Put $0.70

01/30/2012 Sell To Open ONTY Feb12 5 Put $0.50

01/09/2012 Sell To Open ONTY Jan12 5 Put $0.30

Oncothyreon Inc.(ONTY), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer. The company also develops PX-866, a small molecule that is in Phase II trials. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine. The company operates in Canada, the United States, Barbados, and Europe. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Oncothyreon Inc
2601 Fourth Avenue
Suite 500
Seattle, WA 98121
Phone: 206-801-2100
Fax: 206-801-2101
Website:
http://www.oncothyreon.com

News:

PAAS @ $12.14

Hold

there are no good options at this time.

History:

Cost basis $36.00 per share.

Premiums collected: $3.50 per share

Dividends .63c

Total: $4.13

11.04% Return in 43 months

$10,000 would have generated $1104.00

actual trades:

12/11/2013 PAAS – PAAS QUALIFIED DIVIDEND .125

09/06/2013 PAAS – PAAS QUALIFIED DIVIDEND .125

06/19/2013 PAAS – PAAS QUALIFIED DIVIDEND .125

03/19/2013 PAAS – PAAS QUALIFIED DIVIDEND .125

12/04/2012 PAAS – PAAS QUALIFIED DIVIDEND .125

09/24/2012 Sell To Open PAAS Jan13 40 Call $0.05

01/30/2012Sell To Open PAAS Jul12 36 Call $0.20

12/06/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025

10/24/2011 Sell To Open PAAS Jan12 36 Call $0.40

10/22/2011 Buy To Close EXPIRED PAAS Oct11 36 Call

09/08/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025

06/20/2011 Sell To Open PAAS Oct11 36 Call $0.80

06/19/2011 Buy To Close EXPIRED PAAS JUN11 36 CALL

06/16/2011 PAAS QUALIFIED DIVIDEND $.025

05/23/2011 Sell To Open PAAS Jun11 36 Call $0.50

05/20/2011 Buy PAAS – Option Assignment $36.00

05/20/2011 Buy To Close PAAS May11 36 Put $0.00

04/18/2011 Sell To Open PAAS May11 36 Put $1.55

Pan American Silver Corp. engages in the exploration, development, extraction, processing, production, refining, reclamation, and operation of silver properties. The company also produces and sells gold, zinc, lead, and copper. As of April 27, 2011, it had seven silver mining operations in Mexico, Peru, Argentina, and Bolivia. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Pan American Silver Corp.
625 Howe Street
Suite 1500
Vancouver, BC V6C 2T6
Phone: 604-684-1175
Fax: 604-684-0147
Website:
http://www.panamericansilver.com

News:

http://finance.yahoo.com/news/pan-american-silvers-loss-narrows-135002312.html

PAY@ $36.62

VeriFone Systems, Inc.

HOLD : October 14 $44 Call still cooking

History:

Cost basis $43.00 per share.

Premiums collected: $3.76 per share

8.74% Return in 42 months

$10,000 would have generated $839.00

actual trades:

07/21/2014 Sell To Open PAY Oct14 44 Call $0.15

03/24/2014 Sell To Open PAY Jul14 44 Call $0.25

10/22/2012 Sell To Open PAY Jan13 44 Call $0.10

06/18/2012 Sell To Open PAY Oct12 $44 Call $0.35

05/21/2012 Sell To Open PAY Jun12 50 Call $1.00

04/16/2012 Sell To Open PAY May12 57.5 Call $1.02

04/16/2012 Buy To Close PAY Apr12 49 Call -$5.36

01/23/2012 Sell To Open PAY Apr12 49 Call $0.40

01/22/2012 Buy To Close EXPIRED PAY JAN12 49 CALL

10/31/2011 Sell To Open PAY Jan12 49 Call $0.90

10/31/2011 Buy To Close PAY Jan12 46 Call -$1.90

10/24/2011 Sell To Open PAY Jan12 46 Call $1.10

10/22/2011 Buy To Close EXPIRED PAY Oct11 42 Call

08/23/2011 Sell To Open PAY Oct11 42 Call $0.60

08/21/2011 Buy To Close EXPIRED PAY AUG11 46 Call

07/19/2011 Sell To Open PAY Aug11 46 Call $1.05

07/17/2011 Buy To Close EXPIRED PAY JUL11 44 Call

06/20/2011 Sell To Open PAY Jul11 44 Call $0.75

06/17/2011 Buy To Close PAY Jun11 43 Put $0.00

06/17/2011 Buy PAY – Option Assignment $43.00

05/23/2011 Sell To Open PAY Jun11 43 Put $1.70

VeriFone Systems, Inc. designs, markets, and services electronic payment solutions that enable secure electronic payments among consumers, merchants, and financial institutions worldwide. The company provides countertop electronic payment systems that accept magnetic, smart card, and contactless/radio frequency identification cards; and support credit, debit, check, electronic benefits transfer, and various pre-paid products, as well as offers wireless system solutions. The company also provides products for the point of sale applications, which include displays, user-friendly interfaces, electronic cash registers (ECR) interfaces, durable key pads, and signature capture functionality; and contactless/near field communication (NFC) payment solutions for consumer-activated transactions using contactless cards, tokens, or NFC enabled mobile phones. In addition, it offers various products for petroleum companies, such as integrated electronic payment systems that combine card processing, fuel dispensing, and ECR functions, as well as secure payment systems for integration with petroleum pump controllers and systems. Further, the company provides server-based transaction products; secure payment hardware and software integration modules; and VeriShield Protect, a solution that encrypts and protects consumer card data. Additionally, it offers client services, including payment system consulting, deployment, on-site and telephone-based installation and training, help desk support, repairs, replacement of impaired system solutions, asset tracking, and reporting; and project management services. The company serves financial institutions, payment processors, petroleum companies, retailers, government organizations, and healthcare companies, as well as independent sales organizations. The company was formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems, Inc. in May 2010. The company is headquartered in San Jose, California.

VeriFone Systems, Inc
2099 Gateway Place
Suite 600
San Jose, CA 95110
Phone: 408-232-7800
Fax: 408-232-7811
Website:
http://www.verifone.com

News:

http://www.bloomberg.com/news/2014-09-10/verifone-sales-seen-stoked-by-apple-s-mobile-payments.html?cmpid=yhoo

PLUG @ $4.43

Plug Power Inc.

Sell To Open PLUG Nov14 $6 Call @ Market

Bid .11c / Time .12c

History:

Cost basis $6.00 per share.

Premiums collected: .90c per share

15% Return in 5 months

08/18/2014 Sell To Open PLUG Sep14 $6 Call $0.15

05/19/2014 Sell To Open PLUG Aug14 $6 Call $0.35

05/16/2014 Buy PLUG – Stock Assignment $6.00

04/21/2014 Sell To Open PLUG May14 $6 Put $0.40

$10,000 would have generated $1250.00

Plug Power Inc., an alternative energy technology provider, is engaged in the design, development, manufacture, and commercialization of fuel cell systems for the industrial off-road markets worldwide. It is focused on proton exchange membrane (PEM) fuel cell and fuel processing technologies and fuel cell/battery hybrid technologies. The company’s product line includes GenDrive, a hydrogen fueled PEM fuel cell system providing power to material handling vehicles; GenKey, its turn-key solution offering simplicity to customers transitioning their material handling vehicles to fuel cell power; GenFuel, its hydrogen fueling delivery system; and GenCare, its ongoing maintenance program for both the GenDrive fuel cells and GenFuel products. The company sells its products to businesses, government agencies, and commercial consumers through direct product sales force, original equipment manufacturers, and their dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York

Plug Power Inc.
968 Albany Shaker Road
Latham, NY 12110
Phone: 518-782-7700
Website:
http://www.plugpower.com

PRKR @ $1.25

Parkervision Inc.

Hold: No good options at this time

Yes, History:

Cost basis $5.00 per share.

Premiums collected: $1.00 per share

20% Return in 11 months

$10,000 would have generated $2000.00

actual trades:

04/21/2014 Sell To Open PRKR Jul14 $5 Call $0.25

03/24/2014 Sell To Open PRKR Apr14 5.5 Call $0.15

12/23/2013 Sell To Open PRKR Mar14 $6 Call $0.15

11/15/2013 Buy PRKR – Stock Assignment $5.00

10/21/2013 Sell To Open PRKR Nov13 $5 Put $0.45

ParkerVision, Inc. designs, develops, and markets proprietary radio frequency (RF) technologies and products for use in semiconductor circuits for wireless communication products in the United States. It offers its technologies for processing RF waveforms in wireless applications. Its technology applies to both transmit and receive functions of a radio transceiver. The transmit portion of the technology, Direct2Power, enables the transformation of a baseband data signal to an RF carrier waveform at the desired power output level in a single unified operation. The receiver portion of the technology, Direct2Data, enables the direct conversion of an RF carrier to a baseband data signal. The company also provides engineering consulting and design services to its customers to assist them in developing prototypes and/or products incorporating its technologies. It focuses on incorporating its technologies into mobile handsets for 3G and 4G cellular networks, as well as to other wireless products that are related to networks serving mobile handsets, such as tablets, data cards, femtocells, machine-to-machine, and embedded applications. The company’s technology is also used in non-cellular radio applications comprising military radios and cable modems. ParkerVision, Inc. was founded in 1989 and is headquartered in Jacksonville, Florida.

Parkervision Inc.
7915 Baymeadows Way
Suite 400
Jacksonville, FL 32256
Phone: 904-732-6100
Fax: 904-731-0958
Website: http://www.parkervision.com

 

SCTY @ $64.51

solar city corporation

Sell To Open SCTY Oct14 $75 Call @ Market

Bid .72c / Time .79c

History:

Cost basis $75.00 per share.

Premiums collected: $10.20 per share

13.60% Return in 7 months

$10,000 would have generated $1230.00

actual trades:

08/18/2014 Sell To Open SCTY Sep14 $80 Call $0.97

07/21/2014 Sell To Open SCTY Aug14 $80 Call $0.30

04/21/2014 Sell To Open SCTY Jul14 $80 Call $1.31

03/24/2014 Sell To Open SCTY Apr14 80 Call $0.55

03/21/2014 Buy SCTY – Option Assignment $75.00

02/24/2014 Sell To Open SCTY Mar14 75 Put $7.07

SolarCity Corporation engages in the design, installation, and sale or lease of solar energy systems to residential and commercial customers, and government entities in the United States. It provides solar energy systems; and energy efficiency products and services, including home energy evaluation, and energy efficiency upgrade products and services. The company also sells electricity generated by solar energy systems to customers. In addition, it markets and installs electric vehicle charging equipment to residential and commercial customers through retail partnerships. The company was founded in 2006 and is headquartered in San Mateo, California.

SolarCity Corporation
3055 Clearview Way
San Mateo, CA 94402
Phone: 650-638-1028
Fax: 650-638-1029
Website:
http://www.solarcity.com

TRGT @ $2.63

HOLD: No good options at this time

History:

Cost basis $12.50 per share.

Premiums collected: $2.65 per share

21.% Return in 35 months

$10,000 would have generated $21200.00

actual trades:

04/21/2014 Sell To Open TRGT Aug14 $10 Call $0.40

02/21/2012 Sell To Open TRGT May12 15 Call $0.25

11/28/2011 Sell To Open TRGT Feb12 15 Call $0.40

11/18/2011 Buy To Close TRGT Nov11 12.5 Put

11/18/2011 Buy TRGT – Option Assignment $12.50

10/23/2011 Sell to Open TRGT Nov 11 $12.50 PUT $1.60

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. Its lead program, TC-5214, a nicotinic channel modulator, is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder (MDD) and in Phase 2b clinical trial for switch monotherapy in patients with MDD. The company s novel small molecule product candidates under Phase 2 clinical development include TC-5619 for treating negative symptoms and cognitive dysfunction in schizophrenia, attention deficit/hyperactivity disorder, and Alzheimer s disease; AZD3480 as a treatment for mild to moderate Alzheimer s disease; AZD1446 as a treatment for Alzheimer s disease; and TC-6987 for the treatment of inflammatory disorders, including asthma and Type 2 diabetes. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

Targacept, Inc.
200 East First Street
Suite 300
Winston-Salem, NC 27101-4165
Phone: 336-480-2100
Fax: 336-480-2107
Website:
http://www.targacept.com

News:

Earnings report in February

VJET @ $15.36

Voxeljet AG (VJET)

HOLD : No good options at this time

History:

Cost basis $55.00 per share.

Premiums collected: $4.70 per share

8.5% Return in 10 months

$10,000 would have generated $850.00

actual trades:

02/24/2014 Sell To Open VJET May14 $60 Call 0.35c

12/23/2013 Sell To Open VJET Feb14 $60 Call 0.35c

11/18/2013 Sell To Open VJET Dec13 $55 Put $4.00

voxeljet AG provides three-dimensional (3D) printers and on-demand parts services. Its 3D printers employ a powder binding additive manufacturing technology to produce parts using various material sets. The company operates in two segments, Systems and Services. The Systems segment focuses on the production, development, and sale of 3D printers. It also offers consumables, such as particulate materials and proprietary chemical binding agents, maintenance contracts, and spare parts. The Services segment prints on-demand parts at its service center through its 3D printers, material sets, and in-house finishing capabilities. The company provides its 3D printers and on-demand parts services to industrial and commercial customers in automotive, aerospace, film and entertainment, art and architecture, engineering, and consumer product end markets in Europe, the Middle East, Africa, the Asia Pacific, and the Americas. voxeljet AG was founded in 1999 and is headquartered in Friedberg, Germany

Voxeljet AG
Paul-Lenz Strasse 1b
Friedberg, 86316
Germany
Phone: 49 821 7483 100
Fax: 49 821 7483 111
Website:
http://www.voxeljet.de

News:

ZIOP @ $2.92

ZIOPHARM Oncology, Inc.

Hold Oct 14 $5 call is still cooking

History:

Cost basis $3.00 per share.

Premiums collected: $1.25 per share

41.66% Return in 18 months

$10,000 would have generated $4166.00

actual trades:

07/21/2014 Sell To Open ZIOP Oct14 $5 Call $0.35

04/21/2014 Sell To Open ZIOP Jul14 $4 Call $0.30

01/21/2014 Sell To Open ZIOP Apr14 $6 Call $0.35

04/22/2013 Sell To Open ZIOP Jan14 $5 Call $0.05

04/19/2013 Buy ZIOP – Stock Assignment $3.00

03/18/2013 Sell To Open ZIOP Apr13 $3 Put $0.20

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a potent bi-functional DNA alkylating agent, is under Phase III trial for the treatment of first-line metastatic soft tissue sarcoma, as well as in a pivotal Phase III trial for first-line metastatic small cell lung cancer. The company’s portfolio of clinical-stage product candidates also include IL-12 DNA, which is being tested in a Phase 2 study using synthetic biology to enable controlled, local delivery of therapeutic interleukin-12; Indibulin (ZIO-301), a novel, tubulin binding agent under Phase I/II trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial- and hedgehog-targeted agent. In addition, its portfolio comprises various research-stage candidates. The company’s DNA therapeutics are being developed in partnership with Intrexon Corporation through a synthetic biology platform that allows for targeted, controlled production of therapies in humans with a biologic on/off switch. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York with operations center located in Boston, Massachusetts.

ZIOPHARM Oncology, Inc.
1180 Avenue of the Americas
20th Floor
New York, NY 10036
Phone: 646-214-0700
Fax: 646-214-0711
Website:
http://www.ziopharm.com

News:

ZNGA @ $3.06

Hold

Take no action

There are no good options at this time.

History:

Cost basis $14.00 per share.

Premiums collected: $2.05 per share

14.64% Return in 31months

$10,000 would have generated $1464.00

actual trades:

03/19/2012 Sell To Open ZNGA Apr 2012 $16 Call $0.20

03/18/2012 Buy To Close EXPIRED ZNGA MAR12 $15 CALL

02/21/2012 Sell To Open ZNGA Mar12 15 Call $0.40

02/17/2012 Buy ZNGA – Option Assignment $14.00

02/17/2012 Buy To Close ZNGA Feb12 $14 Put

02/06/2012 Sell To Open ZNGA Feb12 14 Put $1.55

Zynga Inc. develops, markets, and operates online social games as live services on the Internet, social networking sites, and mobile platforms. The company offers its online social games under the CityVille, Zynga Poker, FarmVille, CastleVille, FrontierVille, Mafia Wars, Word with Friends, Hidden Chronicles, Zynga Bingo, Scramble With Friends, Slingo, and Dream Heights names. Its games are available on various platforms, including Facebook and other social networks, as well as mobile platforms, such as Apple iOS and Google Android worldwide. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.

Zynga, Inc.
699 Eighth Street
San Francisco, CA 94103
Phone: 855-449-9642
Fax: 302-636-5454
Website:
http://www.zynga.com

News:

Quote of the Month:

Without passion, you don’t have energy. Without energy, you have nothing. “

~ Warren Buffet

Until Next Time

Brad Lee

The Options Oracle

https://theoptionsoracle.com/

The place for safer Investments

 

Established February 2009

Ask The Oracle

Webinar Sunday 8 pm EST to explain this newsletter, or other questions you might have.

Here is the link

https://secure.join.me/BradLeeOptions

There is no preregistration.

Please use the phone option for audio

Summary of Trades:

Cash Covered Puts

Sell To Open SNSS Oct14 $2.50 Put @ Market

Stock Covered Calls

(do not buy into these positions; do not sell unless you already own the stock)

Sell To Open PLUG Nov14 $6 Call @ Market

Sell To Open SCTY Oct14 $75 Call @ Market

Called away:

Nothing called away

Company News

New toll free number:

1-866-466-4617

We cannot return calls to magic jack numbers. Email me for a better number to call

I am slowing down on the videos and will be increasing my Facebook posts.

Please “Like” us on Facebook.

https://www.facebook.com/OptionsOracle

Got a question or concern? Want to learn my philosophy and why it pays so well and consistently? Go to “contact us”

https://theoptionsoracle.com/contact/

and schedule a consultation.

Feel free to contact me personally!

Military discounts are here!

Thank you for your service!

Refer a Friend

The greatest compliment you can give me is to share me with your friends.

Disclosure: These are my actual trades.

I am not telling you what to do, I am showing you what I am doing.

Your subscription fee may be 100% TAX DEDUCTIBLE if used for educational business/investment purposes.Check with your Licensed Professional adviser

 

Company News

Auto Trading is now active!

Don’t want to be bothered doing the trades?

Auto-trading is for you. Your account will automatically do whatever I do.

You are still in control, you set the limits either a dollar amount or a percentage.

Go to the main site, the Auto-trade link is on the site

https://theoptionsoracle.com/auto-trading/

We will be doing a webinar Sunday 8 pm est to explain this newsletter.

Here is the link

https://secure.join.me/BradLeeOptions

Disclosure: These are my actual trades.

Your subscription fee may be 100% TAX DEDUCTIBLE if used for educational business/investment purposes.Check with your Licensed Professional adviser

 

Options involve risk and are not suitable for all investors. Prior to trading options, you must be approved for options trading and read the Characteristics and Risks of Standardized Options.

Copies of this document may also be obtained from your broker, from any exchange on which options are traded, by placing an order online, or by contacting the Options Clearing Corporation directly at 1 N. Wacker Dr., Suite 500, Chicago, IL 60606. (1-888-678-4667).

Brad Lee AKA “The Options Oracle” and “The Money Medic” is an individual investor who does not manage money for any financial institution. You are purchasing the list of stocks that he uses to select options contracts he feels will return him the highest, safest profits. Brad is not a broker, or financial adviser. He is a remarkable investor who has developed a successful strategy for himself, and is willing to share some of his magic with you. We urge you to paper trade these picks and learn how to develop a strategy that is appropriate for you. Thank You.

We make no recommendations on investment and we do not provide financial, tax or legal advice. Content and tools are provided for educational and informational purposes only.

Disclaimer

Trading or investment in stocks, futures & options, and commodity are subject to potential market risks. You can use our materials or recommendations for educational purposes, this is not intended as Trading or Investment advice. We are not financial advisers. We cannot provide any advice as to whether or not options or our trading ideas are suitable investments for your particular financial situation. We are in the business of publishing our trade ideas for market analysis only. We highly recommend that our subscribers review their trading allocation with a qualified registered financial adviser/planner.

Legal Disclaimer: we do not exist to render and do not give legal, tax, economic or investment advice and disclaims all liability for the actions or inaction taken or not as a result of communications from or to its members, officers, directors, employees and contractors. Each individual should consult his/her own counsel, accountant and other advisors as to legal, tax, economic, investment and related matters concerning any type of investments.

This email and any files transmitted with it are solely intended for the use of the addressee(s) and may contain information that is confidential and privileged. If you receive this email in error, please advise us by return email immediately. Please also disregard the contents of the email, delete it and destroy any copies immediately.

In Loving Memory

Ronald E. Lee 1939-2013